Work

Serum c-Myc Levels before Hepatitis C Direct-Acting Antiviral Therapy Could Predict Post-Treatment Hepatocellular Carcinoma

Year: 2026
Type: article
Study design: Observational Study
Abstract: Although direct acting antivirals (DAAs) revolutionized hepatitis C virus (HCV) treatment with great rates of sustained virological response (SVR), it is not fully eliminated hepatocellular carcinoma (HCC) risk. This study aimed to evaluate if pre-treatment circulating c-Myc levels could predict post-treatment HCC in HCV patients who achieved SVR by DAAs. c-Myc was assessed using ELISA in patients who developed and not developed post-treatment HCC. After successful DAAs, patients who developed post-treatment HCC showed significantly (P<0.0001) elevated pre-treatment c-Myc protein (124.8 (99.8-145.6) vs. 62.3 (49.8-85.2) pg/mL; 2-fold elevation) compared to non-HCC patients. At 97 pg/mL, ROC analysis revealed a good c-Myc predictive power (AUC=0.909; P<0.0001) with a sensitivity of 82.2% and specificity of 87.6% in HCC prediction after treatment. Compared to patients with low c-Myc levels (<97 pg/mL), patients who developed post-treatment HCC were more prevalent in cases with elevated c-Myc levels (>97 pg/mL) (86.9% vs. 16.9%). In conclusion, these findings suggesting that c-Myc may be, alone or in combination with other factors, an independent predictor of post-DAA HCC risk.
Author: Mohamed El-Far
Language: English
Subfield: Hepatology
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7217638982
FWCI:
Cites: 30
Cited by:
Related to: 10